Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention.

With the introduction of the target-specific oral anticoagulants (TSOAs), primary and secondary stroke prevention in atrial fibrillation (AF) has been revolutionized. Large randomized clinical trials and subsequent meta-analyses have clearly demonstrated that these agents have at least comparable if not superior efficacy and cause no more or even less major… (More)